Clinical trial evaluation reveals interleukin-6 receptor inhibition controls immunotherapy toxicity, supporting tocilizumab combinations without compromising antitumor immunity.
Targeting IL-6R could be an effective approach to treat several irAE types without hindering antitumor immunity. This study supports ongoing clinical trials evaluating the safety and efficacy of tocilizumab (anti-IL-6R antibody) in combination with ICIs (NCT04940299, NCT03999749).
No takes yet. Share an insight, caveat, or question.
Fa’ak et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: